In Denmark, cardiovascular disease (CVD) causes 12.500 deaths annually (25% of all deaths) and almost 500.000 people are living with CVD, corresponding to 9% of the population. Remarkably, 80% of cardiac events and strokes are preventable; half through early detection and intervention, and uniform secondary prevention gives screening a huge potential, as uniquely shown in our VIVA trial, which reduced overall mortality by 7%. However, current screening tools are too imprecise or impossible to implement.
We will develop a multivariate precision tool, the “KNOW YOUR RISK” test, using unique data not available anywhere else in the world. The innovative test will be developed by machine learning to combine self-reported risks, advanced objective findings, registry data, genomic and proteomic biomarkers. The test will be implemented by OUH together with Medware and Strålfors. It will feature a secure NEM-ID accessible solution for use at home or by general practitioners and physicians. The test has the potential to lower all-cause mortality, CVD morbidity and need for hospital beds by up to 25% within 5 years, thus combatting a major challenge for the society.
Furthermore, social inequality in cardiovascular health will be significantly reduced. In all, the test could save up to DKK 1.33 billion in reduced hospital costs, lower medicine expenses by DKK 0.5 billion, avoid loss of income due to CVD by DKK 0,5 billion and drastically reduce the need for expensive municipal care.